AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own D-Wave, you really have to believe that today’s small, volatile business can turn cutting‑edge quantum hardware and software into sticky, paying customers before cash and patience run thin. The story has always revolved around two catalysts: converting proofs of concept like BASF’s scheduling pilot into larger commercial deals, and convincing deep‑pocketed partners in defense and AI/HPC that D-Wave’s hybrid quantum approach is worth backing despite heavy losses. The new U.S. government unit fits directly into that second pillar, potentially sharpening the company’s focus on federal contracts at a time when Washington is ramping up attention to quantum in the context of U.S.–China competition. That said, the stock’s very large one‑year run, rich price‑to‑book multiple, ongoing dilution and insider selling mean execution risk and downside volatility remain front and center.
However, recent insider selling and ongoing losses are key issues investors should be aware of. Upon reviewing our latest valuation report, D-Wave Quantum's share price might be too optimistic.Explore 90 other fair value estimates on D-Wave Quantum - why the stock might be worth as much as 40% more than the current price!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com